{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hormone+Receptor-Positive+Breast+Carcinoma&page=5", "query": { "condition": "Hormone Receptor-Positive Breast Carcinoma", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 411, "total_pages": 42, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hormone+Receptor-Positive+Breast+Carcinoma&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hormone+Receptor-Positive+Breast+Carcinoma&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-12T03:35:38.904Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05950945", "title": "Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Trastuzumab Deruxtecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 250, "start_date": "2023-12-30", "completion_date": "2027-10-01", "has_results": false, "last_update_posted_date": "2026-06-12", "last_synced_at": "2026-10-12T03:35:38.904Z", "location_count": 5, "location_summary": "Miami Beach, Florida • Tampa, Florida • Boston, Massachusetts + 2 more", "locations": [ { "city": "Miami Beach", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Burlington", "state": "Massachusetts" }, { "city": "Summit", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05950945" }, { "nct_id": "NCT06388122", "title": "DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Breast Cancer Patients", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "HER2-negative Breast Cancer", "Hormone-receptor-positive Breast Cancer", "Metastatic Breast Cancer", "Anatomic Stage II Breast Cancer AJCC v8", "Anatomic Stage III Breast Cancer AJCC v8", "Anatomic Stage IV Breast Cancer AJCC v8", "HER2 Negative Breast Carcinoma", "Hormone Receptor Positive Breast Carcinoma", "Metastatic Breast Carcinoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 100, "start_date": "2024-04-30", "completion_date": "2031-06-15", "has_results": false, "last_update_posted_date": "2026-06-01", "last_synced_at": "2026-10-12T03:35:38.904Z", "location_count": 1, "location_summary": "Jacksonville, Florida", "locations": [ { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06388122" }, { "nct_id": "NCT07287917", "title": "Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Melanoma (Skin Cancer)", "HER2-low Hormone Receptor Positive Breast Cancer" ], "interventions": [ { "name": "AMXT 1501 Dicaprate", "type": "DRUG" }, { "name": "DFMO", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Capivasertib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Aminex Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 92, "start_date": "2026-01-26", "completion_date": "2028-12-29", "has_results": false, "last_update_posted_date": "2026-09-04", "last_synced_at": "2026-10-12T03:35:38.904Z", "location_count": 20, "location_summary": "Tucson, Arizona • La Jolla, California • Los Angeles, California + 15 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Englewood", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT07287917" }, { "nct_id": "NCT01522820", "title": "Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Anaplastic Astrocytoma", "Anaplastic Oligoastrocytoma", "Anaplastic Oligodendroglioma", "Estrogen Receptor Negative", "Estrogen Receptor Positive", "Glioblastoma", "Hormone-Resistant Prostate Cancer", "Metastatic Prostate Carcinoma", "Metastatic Renal Cell Cancer", "Recurrent Adult Brain Neoplasm", "Recurrent Bladder Carcinoma", "Recurrent Breast Carcinoma", "Recurrent Colorectal Carcinoma", "Recurrent Esophageal Carcinoma", "Recurrent Gastric Carcinoma", "Recurrent Hepatocellular Carcinoma", "Recurrent Lung Carcinoma", "Recurrent Melanoma", "Recurrent Ovarian Carcinoma", "Recurrent Prostate Carcinoma", "Recurrent Renal Cell Carcinoma", "Recurrent Uterine Corpus Carcinoma", "Resectable Hepatocellular Carcinoma", "Sarcoma", "Stage IA Breast Cancer", "Stage IA Ovarian Cancer", "Stage IA Uterine Corpus Cancer", "Stage IB Breast Cancer", "Stage IB Ovarian Cancer", "Stage IB Uterine Corpus Cancer", "Stage IC Ovarian Cancer", "Stage II Uterine Corpus Cancer", "Stage IIA Breast Cancer", "Stage IIA Lung Carcinoma", "Stage IIA Ovarian Cancer", "Stage IIB Breast Cancer", "Stage IIB Esophageal Cancer", "Stage IIB Lung Carcinoma", "Stage IIB Ovarian Cancer", "Stage IIB Skin Melanoma", "Stage IIC Ovarian Cancer", "Stage IIC Skin Melanoma", "Stage IIIA Breast Cancer", "Stage IIIA Esophageal Cancer", "Stage IIIA Lung Carcinoma", "Stage IIIA Ovarian Cancer", "Stage IIIA Skin Melanoma", "Stage IIIA Uterine Corpus Cancer", "Stage IIIB Breast Cancer", "Stage IIIB Esophageal Cancer", "Stage IIIB Ovarian Cancer", "Stage IIIB Skin Melanoma", "Stage IIIB Uterine Corpus Cancer", "Stage IIIC Breast Cancer", "Stage IIIC Esophageal Cancer", "Stage IIIC Ovarian Cancer", "Stage IIIC Skin Melanoma", "Stage IIIC Uterine Corpus Cancer", "Stage IV Bladder Urothelial Carcinoma", "Stage IV Esophageal Cancer", "Stage IV Ovarian Cancer", "Stage IV Prostate Cancer", "Stage IV Skin Melanoma", "Stage IVA Uterine Corpus Cancer", "Stage IVB Uterine Corpus Cancer" ], "interventions": [ { "name": "DEC-205/NY-ESO-1 Fusion Protein CDX-1401", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Sirolimus", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "DRUG" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2012-03", "completion_date": "2016-07", "has_results": false, "last_update_posted_date": "2016-10-04", "last_synced_at": "2026-10-12T03:35:38.904Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01522820" }, { "nct_id": "NCT06705504", "title": "A Real-world Study of Effectiveness and Safety in HR+/HER2- Breast Cancer Patients Treated With Ribociclib or Alpelisib", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Hormone Receptor Positive HER-2 Negative Breast Cancer" ], "interventions": [], "intervention_types": [], "sponsor": "Novartis", "sponsor_class": "INDUSTRY", "healthy_volunteers": null, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 435, "start_date": "2021-06-11", "completion_date": "2023-11-30", "has_results": false, "last_update_posted_date": "2024-11-26", "last_synced_at": "2026-10-12T03:35:38.904Z", "location_count": 1, "location_summary": "East Hanover, New Jersey", "locations": [ { "city": "East Hanover", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT06705504" }, { "nct_id": "NCT03251378", "title": "A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors", "Metastatic Colon Cancer", "Metastatic Breast Cancer", "Triple Negative Breast Cancer", "HER2-negative Breast Cancer", "Hormone Receptor Positive Breast Carcinoma", "Rectal Cancer" ], "interventions": [ { "name": "Fruquintinib (HMPL-013)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hutchison Medipharma Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 129, "start_date": "2017-12-11", "completion_date": "2023-03-30", "has_results": true, "last_update_posted_date": "2024-09-25", "last_synced_at": "2026-10-12T03:35:38.904Z", "location_count": 9, "location_summary": "Phoenix, Arizona • San Marcos, California • Santa Rosa, California + 6 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "San Marcos", "state": "California" }, { "city": "Santa Rosa", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Port Saint Lucie", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03251378" }, { "nct_id": "NCT07391774", "title": "Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Anatomic Stage II Breast Cancer AJCC v8", "Anatomic Stage IIIA Breast Cancer AJCC v8", "Anatomic Stage IIIC Breast Cancer AJCC v8", "Estrogen Receptor-Positive Breast Carcinoma", "HER2-Negative Breast Carcinoma" ], "interventions": [ { "name": "Anastrozole", "type": "DRUG" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Scan", "type": "PROCEDURE" }, { "name": "Chemotherapy", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Exemestane", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Oncotype DX Breast Cancer Assay", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Ribociclib Succinate", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1978, "start_date": "2026-08-10", "completion_date": "2029-07-31", "has_results": false, "last_update_posted_date": "2026-10-07", "last_synced_at": "2026-10-12T03:35:38.904Z", "location_count": 201, "location_summary": "Jonesboro, Arkansas • Auburn, California • Berkeley, California + 167 more", "locations": [ { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Auburn", "state": "California" }, { "city": "Berkeley", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Irvine", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07391774" }, { "nct_id": "NCT01385280", "title": "Pilot Study Estradiol Followed by Exemestane Hormone Receptor + Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Estrogen Receptor-positive Breast Cancer", "Progesterone Receptor Positive Tumor", "Recurrent Breast Cancer", "Stage IIIC Breast Cancer", "Stage IV Breast Cancer" ], "interventions": [ { "name": "therapeutic estradiol", "type": "BIOLOGICAL" }, { "name": "exemestane", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "enzyme-linked immunosorbent assay", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "University of Arizona", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "FEMALE", "summary": "Female only" }, "enrollment_count": 13, "start_date": "2011-02", "completion_date": "2013-10", "has_results": true, "last_update_posted_date": "2018-10-17", "last_synced_at": "2026-10-12T03:35:38.904Z", "location_count": 1, "location_summary": "Tucson, Arizona", "locations": [ { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01385280" }, { "nct_id": "NCT00194779", "title": "Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Estrogen Receptor-negative Breast Cancer", "Estrogen Receptor-positive Breast Cancer", "HER2-positive Breast Cancer", "Progesterone Receptor-negative Breast Cancer", "Progesterone Receptor-positive Breast Cancer", "Stage IA Breast Cancer", "Stage IB Breast Cancer", "Stage II Breast Cancer", "Stage IIIA Breast Cancer" ], "interventions": [ { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "capecitabine", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "vinorelbine tartrate", "type": "DRUG" }, { "name": "needle biopsy", "type": "PROCEDURE" }, { "name": "therapeutic conventional surgery", "type": "PROCEDURE" }, { "name": "immunohistochemistry staining method", "type": "OTHER" }, { "name": "trastuzumab", "type": "BIOLOGICAL" }, { "name": "tamoxifen citrate", "type": "DRUG" }, { "name": "letrozole", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "PROCEDURE", "OTHER" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 50, "start_date": "2003-10", "completion_date": "2011-06", "has_results": true, "last_update_posted_date": "2018-03-12", "last_synced_at": "2026-10-12T03:35:38.904Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00194779" }, { "nct_id": "NCT07044310", "title": "5-strain Probiotic Formulation in HR-positive Breast Cancer Receiving Aromatase Inhibitor to Prevent Bone Loss", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anatomic Stage 0 Breast Cancer AJCC v8", "Anatomic Stage I Breast Cancer AJCC v8", "Anatomic Stage II Breast Cancer AJCC v8", "Anatomic Stage III Breast Cancer AJCC v8", "Hormone Receptor-Positive Breast Carcinoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Mineral Density Test", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "WBF-038", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "OTHER", "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 38, "start_date": "2025-07-25", "completion_date": "2027-07-25", "has_results": false, "last_update_posted_date": "2026-08-10", "last_synced_at": "2026-10-12T03:35:38.904Z", "location_count": 1, "location_summary": "Jacksonville, Florida", "locations": [ { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07044310" } ] }